The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
Emerging Concepts and Technologies in Vaccine Development
Open accessAbstract
Despite the success of vaccination to greatly mitigate or eliminate threat of diseases caused by pathogens, there are still known diseases and emerging pathogens for which the development of successful vaccines against them is inherently difficult. In addition, vaccine development for people with compromised immunity and other pre-existing medical conditions has remained a major challenge. Besides the traditional inactivated or live attenuated, virus-vectored and subunit vaccines, emerging non-viral vaccine technologies, such as viral-like particle and nanoparticle vaccines, DNA/RNA vaccines, and rational vaccine design, offer innovative approaches to address existing challenges of vaccine development. They have also significantly advanced our understanding of vaccine immunology and can guide future vaccine development for many diseases, including rapidly emerging infectious diseases, such as COVID-19, and diseases that have not traditionally been addressed by vaccination, such as cancers and substance abuse. This review provides an integrative discussion of new non-viral vaccine development technologies and their use to address the most fundamental and ongoing challenges of vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–260 of 260
Patel, A. R., Walters, J. N., Reuschel, E., Schultheis, K., Parzych, E. M., Gary, E., Maričić, I., Purwar, M., Eblimit, Z., Walker, S. N., et al. (2020) · bioRxiv · doi:10.1101/2020.07.28.225649 · Cited by 62
Vaccines for epidemic infections and the role of CEPI
Plotkin, S. A. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1306615 · Cited by 60
Therapeutic vaccines against tobacco addiction
Fahim, R. E. F., Kessler, P., & Kalnik, M. W. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.13 · Cited by 59
Kramps, T., & Elbers, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_1 · Cited by 57
Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy
Tai, W., Chen, J., Zhao, G., Geng, Q., He, L., Chen, Y., Zhou, Y., Li, F., & Du, L. (2019) · Journal of Virology · doi:10.1128/jvi.02187-18 · Cited by 57
Usher, A. D. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31354-4 · Cited by 57
Jones, S. C., Brahmakshatriya, V., Huston, G., Dibble, J., & Swain, S. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901296 · Cited by 54
Dimmock, N. J., Dove, B. K., Scott, P. D., Meng, B., Taylor, I., Cheung, L., Hallis, B., Marriott, A. C., Carroll, M. W., & Easton, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049394 · Cited by 54
Kennedy, N. J., Spithill, T. W., Tennent, J. M., Wood, P. R., & Piedrafita, D. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.076 · Cited by 53
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
Rüedi‐Bettschen, D., Wood, S. L., Gunnell, M. G., West, C. M., Pidaparthi, R. R., Carroll, F. I., Blough, B. E., & Owens, S. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.038 · Cited by 53
Singer, C. F., Pfeiler, G., Hubalek, M., Bartsch, R., Stöger, H., Pichler, A., Petru, E., Bjelic‐Radisic, V., Greil, R., Rudas, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.018 · Cited by 53
Pravetoni, M., Vervacke, J. S., Distefano, M. D., Tucker, A. M., Laudenbach, M., & Pentel, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096547 · Cited by 52
Biologics to treat substance use disorders: Current status and new directions
Pravetoni, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1212785 · Cited by 52
Uchida, S., Yoshinaga, N., Yanagihara, K., Yuba, E., Kataoka, K., & Itaka, K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.033 · Cited by 52
The Antiviral and Antitumor Effects of Defective Interfering Particles/Genomes and Their Mechanisms
Yang, Y., Lyu, T., Zhou, R., He, X., Ye, K., Xie, Q., Zhu, L., Chen, T., Shen, C., Wu, Q., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01852 · Cited by 52
Kimishima, A., Wenthur, C. J., Zhou, B., & Janda, K. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00977 · Cited by 49
Elliott, S. T. C., Kallewaard, N. L., Benjamin, E., Wachter-Rosati, L., McAuliffe, J. M., Patel, A. R., Smith, T. R. F., Schultheis, K., Park, D. H., Flingai, S., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0020-x · Cited by 49
Toward rational antibody design: recent advancements in molecular dynamics simulations.
Yamashita, T. (2018) · International Immunology · doi:10.1093/intimm/dxx077 · Cited by 49
Li, S. S., Kochar, N. K., Elizaga, M. L., Hay, C. M., Wilson, G. J., Cohen, K. W., Rosa, S. C. D., Xu, R., Ota‐Setlik, A., Morris, D. E., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00263-17 · Cited by 48
Investigating Hapten Clustering as a Strategy to Enhance Vaccines against Drugs of Abuse
Collins, K. C., & Janda, K. D. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500016k · Cited by 47
Rational Epitope Design for Protein Targeting
Peri, C., Gagni, P., Combi, F., Gori, A., Chiari, M., Longhi, R., Cretich, M., & Colombo, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300487u · Cited by 47
CONDIT, R. C., Williamson, A., Sheets, R., Seligman, S. J., Monath, T. P. C., Excler, J., Gurwith, M., Bok, K., Robertson, J. S., Kim, D., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.060 · Cited by 46
Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer
Tan, Y. S., Sansanaphongpricha, K., Prince, M. E., Sun, D., Wolf, G. T., & Lei, Y. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518764416 · Cited by 46
Covid-19: Russia approves vaccine without large scale testing or published results
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m3205 · Cited by 45
Scott, P. D., Meng, B., Marriott, A. C., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.114 · Cited by 44
Keck, M.-L., Wrensch, F., Pierce, B. G., Baumert, T. F., & Foung, S. K. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01194 · Cited by 44
McCluskie, M. J., Thorn, J. M., Gervais, D. P., Stead, D. R., Zhang, N., Benoit, M., Cartier, J., Kim, I.-J., Bhattacharya, K., Finneman, J. I., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.012 · Cited by 42
Methamphetamine Vaccines: Improvement through Hapten Design
Collins, K. C., Schlosburg, J. E., Bremer, P. T., & Janda, K. D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00084 · Cited by 42
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity
Li, Z., Song, S., He, M., Wang, D., Shi, J., Liu, X., Li, Y., Chi, X., Wei, S., Yang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07199-6 · Cited by 42
Ong, E., Wong, M. U., & He, Y. O. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01382 · Cited by 40
Single-cycle adenovirus vectors in the current vaccine landscape
Barry, M. A. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419067 · Cited by 40
Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response
Arab, A., Nicastro, J., Slavcev, R. A., Razazan, A. P., Barati, N., Nikpoor, A. R., Momtazi‐Borojeni, A. A., Mosaffa, F., Badiee, A., Jaafari, M. R., et al. (2017) · Immunologic Research · doi:10.1007/s12026-017-8969-0 · Cited by 39
McCluskie, M. J., Thorn, J. M., Mehelic, P., Kolhe, P., Bhattacharya, K., Finneman, J. I., Stead, D. R., Piatchek, M. B., Zhang, N., Chikh, G., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.02.030 · Cited by 38
Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids
Englezou, P. C., Sapet, C., Démoulins, T., Milona, P., Ebensen, T., Schulze, K., GUZMAN, C., Poulhès, F., Zelphati, O., Ruggli, N., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.019 · Cited by 38
Dhanwani, R., Zhou, Y., Huang, Q., Verma, V., Dileepan, M., Ly, H., & Liang, Y. (2015) · Journal of Virology · doi:10.1128/jvi.02705-15 · Cited by 37
Self-citationGilbert, S. C., & Warimwe, G. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.085 · Cited by 35
COVID‐19 vaccines: Knowing the unknown
Lv, H., Wu, N. C., & Mok, C. K. P. (2020) · European Journal of Immunology · doi:10.1002/eji.202048663 · Cited by 34
CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells
Franco, D., Liu, W., Gardiner, D., Hahn, B. H., & Ho, D. D. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820b844e · Cited by 33
Carossino, M., Wagner, B., Loynachan, A. T., Cook, R. F., Canisso, I. F., Chelvarajan, L., Edwards, C. L., Nam, B., Timoney, J. F., Timoney, P. J., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00215-17 · Cited by 32
Haidari, G., Cope, A. V., Miller, A., Venables, S., Yan, C., Ridgers, H., Reijonen, K., Hannaman, D., Spentzou, A., Hayes, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13331-1 · Cited by 31
Defective interfering virus protects elderly mice from influenza
Scott, P. D., Meng, B., Marriott, A. C., Easton, A. J., & Dimmock, N. J. (2011) · Virology Journal · doi:10.1186/1743-422x-8-212 · Cited by 30
Cornish, K. E., de Villiers, S. H. L., Pravetoni, M., & Pentel, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082557 · Cited by 28
Andreasson, K., Tegerstedt, K., Eriksson, M., Curcio, C., Cavallo, F., Forni, G., Dalianis, T., & Ramqvist, T. (2008) · International Journal of Cancer · doi:10.1002/ijc.23920 · Cited by 28
Self-Replicating RNA Vaccine Delivery to Dendritic Cells
Démoulins, T., Englezou, P. C., Milona, P., Ruggli, N., Tirelli, N., Pichon, C., Sapet, C., Ebensen, T., Guzmán, C. A., & McCullough, K. C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_3 · Cited by 27
Zhou, H., Guo, L., Wang, M., Qu, J., Zhao, Z., Wang, J., & Hung, T. (2011) · Virology Journal · doi:10.1186/1743-422x-8-3 · Cited by 26
Active vaccination attenuates the psychostimulant effects of α-PVP and MDPV in rats
Nguyen, J. D., Bremer, P. T., Ducime, A., Creehan, K. M., Kisby, B. R., Taffe, M. A., & Janda, K. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.005 · Cited by 25
Townsend, E. A., & Banks, M. L. (2020) · CNS Drugs · doi:10.1007/s40263-020-00722-8 · Cited by 25
Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine
Zhou, T., & Xu, K. Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_4 · Cited by 24
Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence
Uccellini, M. B., Busto, P., Debatis, M. E., Marshak‐Rothstein, A., & Viglianti, G. A. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.01.003 · Cited by 22
Seib, K. G., Pollard, A. J., Wals, P. D., Andrews, R. M., Zhou, F., Hatchett, R. J., Pickering, L. K., & Orenstein, W. A. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.10.080 · Cited by 21
Stanberry, L. R., & Strugnell, R. A. (2011) · Perspectives in Vaccinology · doi:10.1016/j.pervac.2011.05.006 · Cited by 20
Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Lukschal, A., Stremnitzer, C., Roth‐Walter, F., Weghofer, M., Ritter, M., Tossi, K. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1171446 · Cited by 20
Zupančič, E., Curato, C., Kim, J., Yeini, E., Porat, Z., Viana, A. S., Levin, A. G., Waks, T., Eshhar, Z., Moreira, J. N., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.011 · Cited by 19
Virus-like antigen display for cancer vaccine development, what is the potential?
Sander, A. F., & Lollini, P. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1455505 · Cited by 19
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial
Huang, Y., DiazGranados, C. A., Janes, H., Huang, Y., deCamp, A. C., Metch, B. J., Grant, S., Sanchez, B., Phogat, S. K., Koutsoukos, M., et al. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.01.007 · Cited by 14
Covid-19: Where are we on immunity and vaccines?
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m3096 · Cited by 12
Evolution of rational vaccine designs for genital herpes immunotherapy
Kaufmann, J. K., & Flechtner, J. B. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.01.021 · Cited by 10
Rational Design of T Lymphocyte Epitope-Based Vaccines Against Coccidioides Infection
Hurtgen, B. J., & Hung, C.-Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7104-6_4 · Cited by 7
Bhagawati-Prasad, V., Leenheer, E. D., Keefe, N. P., Ryan, L. A., Carlring, J., & Heath, A. W. (2010) · Journal of Immune Based Therapies and Vaccines · doi:10.1186/1476-8518-8-1 · Cited by 5
Becker, P. D., & Guzmán, C. A. (2004) · Transfusion Medicine and Hemotherapy · doi:10.1159/000082484 · Cited by 3
Cited by
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D’Aoust, M.-A., Dhaliwall, J., Finkle, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01370-1 · Cited by 360
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 285
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Rahman, A., Islam, M. J., Karim, M. R., Kundu, D., & Kabir, S. (2021) · 2021 International Conference on Electronics, Communications and Information Technology (ICECIT) · doi:10.1109/icecit54077.2021.9641303 · Cited by 21
Metadata
- Authors
- Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-30
- Volume
- 11
- Pages
- 583077-583077
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3089805074
- Cited by
- 323
- References
- 260
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.